Journal: JCI Insight

Article Title: Multipanel mass cytometry reveals anti–PD-1 therapy–mediated B and T cell compartment remodeling in tumor-draining lymph nodes

doi: 10.1172/jci.insight.132286

Figure Lengend Snippet: (A) MC38 tumor cells were injected subcutaneously at day 0 (D0) in the right hind limb of C57BL/6 mice, and either isotype (ISO) or PD-1 antibody (PD-1) was administered intraperitoneally on D14 and D18. Right inguinal lymph nodes were harvested on D21 for analysis. Lymph nodes at the same location from normal, non–tumor-bearing mice (NL) were used as additional control comparators. (B) Lymph nodes were weighed on D21 upon harvest, and (C) absolute number of cells was counted from each lymph node. Mean ± SD (n = 5) are shown for both plots. (D) Schematic shows how lymph nodes from each respective group (Normal LN, non–tumor-bearing normal mice; tdLN Isotype, isotype-treated tumor-bearing mice; tdLN PD-1, PD-1–antibody–treated tumor-bearing mice) were barcoded with a specific CD45 antibody tagged with a unique metal to be multiplexed and stained with a T or B cell subtyping mass cytometry panel. Results for repeated-measures ANOVA followed by pairwise testing are shown as FDR-adjusted *P ≤ 0.05; **P ≤ 0.01; and ***P ≤ 0.005.

Article Snippet: MC38 (Kerafast) cells were maintained in DMEM-based medium containing 10% FBS, 1% l -glutamine, 100 U/mL penicillin/streptomycin, 10 mM HEPES, 1 mM sodium pyruvate, and 0.1 mM nonessential amino acids (Life Technologies) in 5% CO 2 at 37°C.

Techniques: Injection, Staining, Mass Cytometry

Journal: Cell reports

Article Title: HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation

doi: 10.1016/j.celrep.2023.113352

Figure Lengend Snippet: (A and B) Tumor growth (A) and survival curves (B) of C57BL/6J mice inoculated with control or HRS KO B16F10 melanoma cells. (C and D) Tumor growth (C) and survival curves (D) of athymic nude mice inoculated with control or HRS KO B16F10 melanoma cells. (E and F) Tumor growth (E) and survival curves (F) of C57BL/6J mice inoculated with control or HRS KD MC38 colon cancer cells. (G and H) Tumor growth (G) and survival curves (H) of athymic nude mice inoculated with control or HRS KD MC38 colon cancer cells. (I and J) Tumor growth (I) and survival curves (J) of C57BL/6J mice inoculated with control or HRS KO B16F10 cells, and the mice were intraperitoneally injected with isotype or anti-CD8 antibodies. (K and L) Tumor growth (K) and survival curves (L) of C57BL/6J mice inoculated with control, HRS KO B16, B2M KO, or HRS B2M double KO (dKO) B16F10 cells. Data represent the mean ± SEM; n = 7 or 8 immunocompetent C57BL/6J mice per group, n = 5 or 7 athymic nude mice per group. The p values were determined by two-way ANOVA (A, C, E, G, I, and K) or log-rank test (B, D, F, H, J, and L). See also and .

Article Snippet: Mouse cell line: MC38 , Serge Y. Fuchs, Penn Veterinary School of Medicine , PMID: 32807917; RRID:CVCL_B288.

Techniques: Control, Injection

Journal: Cell reports

Article Title: HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation

doi: 10.1016/j.celrep.2023.113352

Figure Lengend Snippet: (A and B) Immunohistochemistry (A) with quantification (B) of CD45 + immune cells (left) and CD8 + T cells (right) in control and HRS KO B16F10 tumors. (C) The infiltration of CD4 + (left) and CD8 + (right) lymphocytes (tumor-infiltrating lymphocytes [TILs]) from control and HRS KO B16F10 tumors in C57BL/6J mice. (D) The expression of Ki-67 (left) and GzmB (right) by CD8 + TILs from control and HRS KO B16F10 tumors. (E) The infiltration of CD4 + (left) and CD8 + (right) TILs from control and HRS KD MC38 colon tumors in C57BL/6J mice. (F) The expression of Ki-67 (left) and GzmB (right) by CD8 + TILs from control and HRS KD MC38 colon tumors. Data represent the mean ± SD; n = 7 or 8 mice per group. The p values were determined by unpaired Student’s t test (B–F). See also .

Article Snippet: Mouse cell line: MC38 , Serge Y. Fuchs, Penn Veterinary School of Medicine , PMID: 32807917; RRID:CVCL_B288.

Techniques: Immunohistochemistry, Control, Expressing

Journal: Cell reports

Article Title: HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation

doi: 10.1016/j.celrep.2023.113352

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Mouse cell line: MC38 , Serge Y. Fuchs, Penn Veterinary School of Medicine , PMID: 32807917; RRID:CVCL_B288.

Techniques: Virus, Recombinant, SYBR Green Assay, Staining, shRNA, Plasmid Preparation, Software, CRISPR